Reducing time to antibiotic administration for febrile neutropenia in the emergency department

Journal of Oncology Practice

Volumn 11, Issue 6, 2015, Pages 450-455

  Keng, Michael K ^a   Thallner, Elaine A ^a   Elson, Paul ^a   Ajon, Christine ^a   Sekeres, Jennifer ^a   Wenzell, Candice M ^a   Seastone, David J ^a   Gallagher, Erika M ^a   Weber, Catherine M ^a   Earl, Marc A ^a   Mukherjee, Sudipto ^a   Pohlman, Brad ^a   Cober, Eric ^a   Foster, Virginia B ^a   Yuhas, Joy ^a   Kalaycio, Matt E ^a   Bolwell, Brian J ^a   Sekeres, Mikkael A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BREAST CANCER; CANCER PATIENT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EMERGENCY CARE; EMERGENCY HEALTH SERVICE; EMERGENCY WARD; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LEUKEMIA; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; THERAPY DELAY; TIME TO TREATMENT; HOSPITALIZATION; LENGTH OF STAY; MIDDLE AGED; NEOPLASMS; STATISTICS AND NUMERICAL DATA; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; EMERGENCY SERVICE, HOSPITAL; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NEOPLASMS; TIME FACTORS; YOUNG ADULT;

EID: 84947236259     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2014.002733     Document Type: Article

References (23)

1. Crawford J, Dale DC, Lyman GH: Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management. Cancer 100:228-237, 2004
2. Gafter-Gvili A., Fraser A, Paul M., et al: Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979-995, 2005
3. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Prevention and treatment of cancer-related infections: Version 1. 2013: www.nccn.org
4. Pizzo PA: Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323-1332, 1993
5. Kuderer NM, Dale DC, Crawford J, et al: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258-2266, 2006
6. Wingard JR, Elmongy M: Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibiotics. Crit Rev Oncol Hematol 72:144-154, 2009
7. Freifeld AG, Bow EJ, Sepkowitz K.A., et al: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56-e93, 2011
8. Legrand M, Max A, Peigne V., et al: Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 20:43-49, 2012
9. Flowers CR, Seidenfeld J, Bow E.J., et al: Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31:794-810, 2013
10. Perrone J, Hollander JE, Datner EM: Emergency department evaluation of patients with fever and chemotherapy-induced neutropenia. J Emerg Med 27: 115-119, 2004
11. Courtney DM, Aldeen AZ, Gorman S.M., et al: Cancer-associated neutropenic fever: Clinical outcome and economic costs of emergency department care. Oncologist 12:1019-1026, 2007
12. Bernstein SL, Aronsky D, Duseja R., et al: The effect ofemergency department crowding in clinically oriented outcomes. Acad Emerg Med 16:1-10, 2009
13. Agency for Healthcare Research and Quality: Emergency Severity Index (ESI): A Triage Tool for Emergency Department: Version 4. http://www.ahrq.org
14. Dellinger RP, Levy MM, Rhodes A, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41:580-637, 2013
15. Talcott JA, Finberg R, Mayer R.J., et al: The medical course of cancer patients with fever and neutropenia: Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148:2561-2568, 1988
16. Talcott JA, Siegel RD, Finberg R, et al: Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316-322, 1992
17. Klastersky J, Paesmans M, Rubenstein E.B., et al: The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038-351, 2000
18. Klastersky J, Paesmans M, Georgala A., et al: Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129-4134, 2006
19. Darmon M, Azoulay E, Alberti C., et al: Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients. Intensive Care Med 28:1775-1780, 2002
20. Wisplinghoff H, Seifert H, Wenzel R.P., et al: Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36:1103-1120, 2003
21. Lin MY, Weinstein RA, Hota B: Delay of active antimicrobial therapy and mortality among patients with bacteremia: Impact of severe neutropenia. Antimicrob Agents Chemother 52:3188-194, 2008
22. Burry E, Punnett A, Mehta A., et al: Identification of educational and infrastructural barriers to prompt antibiotic delivery in febrile neutropenia: A quality improvement initiative. Pediatr Blood Cancer 59:431-435, 2012
23. Perron T, Emara M, Ahmed S: Time to antibiotics and outcomes in cancer patients with febrile neutropenia. BMC Health Serv Res 14:162, 2014